REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Natural GH Pulse

GH Optimizationbeginner

90

synergy

90
Share
Peptides

2

Avg Daily mcg

300

Level

beginner

Added

May 17, 2026

Overview

The Natural GH Pulse stack combines a growth hormone releasing hormone (GHRH) analog with a selective growth hormone secretagogue to produce amplified, pulsatile GH release that mimics the body''s natural rhythm. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a truncated and modified analog of endogenous GHRH that stimulates the pituitary to produce growth hormone. Its short half-life (approximately 30 minutes) means it generates discrete GH pulses rather than sustained elevation, preserving the body''s natural feedback mechanisms. Ipamorelin is a pentapeptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering GH release without significantly affecting cortisol, prolactin, or ACTH levels — making it the cleanest growth hormone secretagogue available. Unlike older secretagogues such as GHRP-6, Ipamorelin does not stimulate appetite or raise cortisol, making it suitable for long-term use. The synergy between CJC-1295 (no DAC) and Ipamorelin is well-documented: GHRH analogs and ghrelin-mimetics act through different receptors on the same pituitary cells, producing an amplified GH pulse approximately 3-5x greater than either peptide alone. This phenomenon is called the "GH synergy effect" and has been demonstrated in human clinical studies. The combined pulse mimics the magnitude of youthful GH secretion while maintaining pulsatility, which is critical for avoiding GH receptor desensitization. Benefits include improved sleep architecture (deeper slow-wave sleep), enhanced recovery from exercise, modest fat reduction, and improved skin quality over 3-6 months of consistent use.

Dosing Protocol

CJC-1295 (no DAC)

Every day· subcutaneous

Read more about CJC-1295 (no DAC) →

100 mcg

per dose

Ipamorelin

Every day· subcutaneous

Read more about Ipamorelin →

200 mcg

per dose

Goals & Evidence

Growth hormoneAnti-agingFat lossSleep qualityRecovery
Evidence tier:Human RCT

Warnings

  • CJC-1295 and Ipamorelin are both FDA Category 2 pending reclassification. Do not use with active cancer.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.